Antigen-negative Relapse
Antigen-negative Relapse - Related Videos
26:48
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
0 Views •
Cited by 27 •
2007
This video demonstrates the induction and clinical scoring of an animal model of multiple sclerosis: chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. The disease, induced by immunizing rats with an emulsion containing whole rat spinal cord and complete Freund's adjuvant, presents clinical signs resembling the human disease.
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
0 Views •
2025
The protocol aims to describe a mouse model for generating relapses of acute lymphoblastic leukemia, based on the dynamics of the response to induction chemotherapy.
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
0 Views •
Cited by 2 •
2015
Combining plot analysis with trigonometric regression is a robust method for exploring complex, cyclical phenomena such as relapse onset timing in multiple sclerosis (MS). This method enabled unbiased characterisation of seasonal trends in relapse onset permitting novel inferences around the influence of seasonal variation, ultraviolet radiation (UVR) and latitude.
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
0 Views •
Cited by 9 •
2016
In this antigen-driven colitis model, OT-II CD4+ T cells expressing a red fluorescent protein were adoptively transferred into RAG-/- mice that express a green fluorescent protein in mononuclear phagocytes (MPs). The hosts were challenged with Escherichia coli (E.coli) expressing the ovalbumin protein (OVA) fused to a cyan fluorescent protein (CFP).
04:27
Isolation of Monocytes from Whole Blood by Immunomagnetic Negative Selection
0 Views •
2025
In this video, we demonstrate the isolation of monocytes from whole human blood by immunomagnetic negative separation. The isolated monocytes can be used for further downstream analysis.
FAQs
Several biological routes can produce antigen-negative relapse. A recurrent cell may acquire a genetic alteration, use alternative splicing, or undergo a lineage change that removes or alters the targeted antigen. These mechanisms change the cell’s visible molecular profile, so an immune response or therapy selected for the original antigen may no longer recognize the recurrent population.
Treatment pressure can favor pre-existing antigen-negative cells, allowing them to expand while antigen-positive cells are suppressed. This route differs from relapse caused by a newly acquired alteration because the escape-capable population was already present before treatment. Recognizing this possibility helps explain why an initially effective antigen-specific intervention may be followed by recurrence with a changed antigen profile.
Alternative splicing and lineage change are important because they can modify antigen display without requiring the same route of genetic alteration. Either process may produce recurrent cells with a different recognizable profile, weakening an antigen-specific intervention. Considering these mechanisms broadens analysis of relapse beyond simple treatment failure and directs attention to how cellular identity or antigen display has changed.
Loss of the target can block recognition by more than one immune effector. Antigen-specific T cells depend on displaying the relevant antigen, while antibodies also require access to their targeted antigen. Consequently, recurrence can persist despite a previously active antigen-focused response when the recurrent cells no longer present that molecular target.
Antigen monitoring supports both diagnosis and surveillance by showing whether the disease-associated target remains present when disease returns. A change from detectable antigen to antigen-negative status can provide context for treatment failure and persistence, rather than treating every recurrence as biologically identical. Repeated attention to antigen status helps connect disease behavior with immune escape.
Multi-antigen therapies can reduce reliance on a single molecular target, making antigen loss less sufficient to produce immune escape. Strategies directed at essential, less variable molecules may also lower the risk that recurrence will evade recognition through target change. These approaches address the vulnerability created when treatment depends on an antigen that recurrent cells can lose.
Antigen-negative relapse helps researchers investigate how malignant or infected cells persist when an immune response or therapy has selected for target loss. Studying this pattern connects recurrence with immune escape and clarifies why treatment can fail after an initial response. The same framework supports interpretation of disease persistence across both cancer-related and infection-related settings.